Carl von Linnékliniken Group is a leading fertility treatment clinic based in Uppsala offering various treatments such as IVF, IUI and gamete donation.
Vinge has advised VEF Ltd, an investment company whose Swedish Depositary Receipts (“SDR”) are listed on Nasdaq First North, in connection with a directed share issue whereby VEF receives approximately SEK 522 million in issue proceeds.
PointSharp provides security solutions which enable enterprises to secure the login of their users to all their applications through e.g. multi-factor authentication, with a simplified user experience. PointSharp serves more than 220 customers globally.
Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue in the pharmaceutical company Xbrane Bipharma, whereby Xbrane Biopharma receives gross proceeds of approximately SEK 200 million.
Diagnostiskt Centrum Hud, the leading provider of medical dermatology services in Sweden, partnered with Bridgepoint Growth to further support the company’s expansion.
Vinge assisted the STRAX group in refinancing and the entering into a facilities agreement with Proventus Capital Partners IV (“Proventus”) as lender in the total amount of EUR 30 million.
Vinge has advised Offentliga Hus i Norden AB (publ) (“Offentliga Hus”) in connection with its listing on Nasdaq First North Premier Growth Market (“Nasdaq First North Premier”). The prospectus was published on 13 October 2020 and the first day of trading on Nasdaq First North Premier was 23 October 2020.
Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.
